Global Biologics Contract Development And Manufacturing Organization (cdmo) Market Size & Outlook

The global biologics contract development and manufacturing organization (cdmo) market size was estimated at USD 47,837.7 million in 2025 and is projected to reach USD 84,911.1 million by 2033, growing at a CAGR of 7.4% from 2026 to 2033.
Revenue, 2025 (US$M)
$47,837.7
Forecast, 2033 (US$M)
$84,911.1
CAGR, 2026 - 2033
7.4%
Report Coverage
Worldwide

Global biologics contract development and manufacturing organization (cdmo) market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

Global biologics contract development and manufacturing organization (cdmo) market highlights

  • The global biologics contract development and manufacturing organization (cdmo) market generated a revenue of USD 47,837.7 million in 2025 and is expected to reach USD 84,911.1 million by 2033.
  • The market is expected to grow at a CAGR (2026 - 2033) of 7.4% by 2033.
  • In terms of segment, monoclonal antibodies (mabs) accounted for a revenue of USD 21,442.8 million in 2025.
  • Nucleic Acid Therapeutics is the most lucrative product segment registering the fastest growth during the forecast period.
  • In terms of region, North America was the largest revenue generating market in 2025.
  • Country-wise, China is expected to register the highest CAGR from 2026 to 2033.

Global data book summary

Market revenue in 2025USD 47,837.7 million
Market revenue in 2033USD 84,911.1 million
Growth rate7.4% (CAGR from 2026 to 2033)
Largest segmentMonoclonal antibodies (mabs)
Fastest growing segmentNucleic Acid Therapeutics
Historical data covered2021 - 2024
Base year for estimation2025
Forecast period covered2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationMonoclonal Antibodies (mAbs), Recombinant Proteins & Enzymes, Vaccines, Cell & Gene Therapies, Nucleic Acid Therapeutics, Other Product

Other key industry trends

  • In terms of revenue, the North America accounted for 43.8% of the global biologics contract development and manufacturing organization (cdmo) market in 2025.
  • By country, the U.S. is projected to lead the global market in terms of revenue in 2033.
  • By country, China is the fastest growing regional market and is projected to reach USD 4,944.9 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Biologics Contract Development And Manufacturing Organization (CDMO) Market Companies

Name Profile # Employees HQ Website
Sandoz View profile 10001+ Holzkirchen, Bayern, Germany, Europe https://www.sandoz.de
Fujifilm Diosynth Biotechnologies U.S.A., Inc. View profile - - -
Vetter Pharma View profile - - -
WuXi Biologics. View profile - - -
Lonza View profile - - -
GenScript View profile - - -
Charles River Laboratories International Inc. View profile - - -
Catalent Pharma Solutions View profile 5001-10000 Somerset, New Jersey, United States, North America http://www.catalent.com
IDT Biologika View profile 1001-5000 Dessau, Sachsen-Anhalt, Germany, Europe https://idt-biologika.de/
Samsung BioLogics View profile 1001-5000 Incheon, Inch'on-jikhalsi, South Korea, Asia https://www.samsungbiologics.com/
AGC Biologics View profile 1001-5000 Bothell, Washington, United States, North America http://www.agcbio.com/
Rentschler Biopharma SE View profile 501-1000 Laupheim, Baden-Wurttemberg, Germany, Europe https://www.rentschler-biopharma.com
Siegfried Holding AG View profile 4180 Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 https://www.siegfried.ch
Boehringer Ingelheim View profile 10001+ Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe https://www.boehringer-ingelheim.com/
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com

Global biologics contract development and manufacturing organization (cdmo) market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development and manufacturing organization (cdmo) market will help companies and investors design strategic landscapes.


Monoclonal antibodies (mabs) was the largest segment with a revenue share of 44.82% in 2025. Horizon Databook has segmented the Global biologics contract development and manufacturing organization (cdmo) market based on monoclonal antibodies (mabs), recombinant proteins & enzymes, vaccines, cell & gene therapies, nucleic acid therapeutics, other product covering the revenue growth of each sub-segment from 2021 to 2033.


  • Global Biologics Contract Development And Manufacturing Organization (CDMO) Product Outlook (Revenue, USD Million, 2021-2033)
    • Monoclonal Antibodies (mAbs)
    • Recombinant Proteins & Enzymes
    • Vaccines
    • Cell & Gene Therapies
    • Nucleic Acid Therapeutics
    • Other Product
  • Global Biologics Contract Development And Manufacturing Organization (CDMO) Service Outlook (Revenue, USD Million, 2021-2033)
    • Packaging and Labelling
    • Regulatory Affairs
    • Logistics & Storage
    • Other Service
    • Contract Development
      • Cell Line Development
      • Analytical Testing & Method Validation
      • Scale-Up & Tech Transfer
      • Process Development
        • Upstream
        • Downstream
    • Contract Manufacturing
      • API Manufacturing
      • Finished Drug Products Manufacturing
  • Global Biologics Contract Development And Manufacturing Organization (CDMO) Source Outlook (Revenue, USD Million, 2021-2033)
    • Mammalian
    • Microbial
  • Global Biologics Contract Development And Manufacturing Organization (CDMO) Workflow Outlook (Revenue, USD Million, 2021-2033)
    • Commerical
    • Clinical
  • Global Biologics Contract Development And Manufacturing Organization (CDMO) Therapeutic Area Outlook (Revenue, USD Million, 2021-2033)
    • Oncology
    • Autoimmune Diseases
    • Infectious Diseases
    • Cardiovascular Diseases
    • Metabolic Diseases
    • Neurological Diseases
    • Other Therapeutic Area
  • Global Biologics Contract Development And Manufacturing Organization (CDMO) End Use Outlook (Revenue, USD Million, 2021-2033)
    • Pharmaceutical Companies
    • Biotechnology Companies
    • Academic and Research Institutions
    • Other End Use

Reasons to subscribe to Global biologics contract development and manufacturing organization (cdmo) market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Global biologics contract development and manufacturing organization (cdmo) market databook

  • Our clientele includes a mix of biologics contract development and manufacturing organization (cdmo) market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of global-level data and insights on the Global biologics contract development and manufacturing organization (cdmo) market , including forecasts for subscribers. This global databook contains high-level insights into Global biologics contract development and manufacturing organization (cdmo) market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Global biologics contract development and manufacturing organization (cdmo) market size, by regions, 2021-2033 (US$M)

Top 10 countries: Biologics contract development and manufacturing organization (cdmo) market size, 2025 (US$M)

Global biologics contract development and manufacturing organization (cdmo) market share, by product, 2025 & 2033 (%, US$M)

Biologics contract development and manufacturing organization (cdmo) market: Opportunity assessment by country

Global biologics contract development and manufacturing organization (cdmo) market, by region, 2025 (US$M)

Global biologics contract development and manufacturing organization (cdmo) market size, by regions, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online